InventisBio Co., Limited (SHA:688382)
China
· Delayed Price · Currency is CNY 33.90
-0.35 (-1.02%)
At close: Jun 26, 2025, 2:57 PM CST
InventisBio Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 168.37 | 168.79 | 185.53 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | -13.27% | -9.02% | - | - | - | - | Upgrade
|
| Cost of Revenue | 1.03 | 3.92 | - | - | - | - | Upgrade
|
| Gross Profit | 167.34 | 164.87 | 185.53 | - | - | - | Upgrade
|
| Selling, General & Admin | 52.27 | 52.5 | 60.85 | 57.96 | 47.71 | 23.69 | Upgrade
|
| Research & Development | 360.27 | 384.35 | 442.91 | 461.49 | 315.04 | 1,005 | Upgrade
|
| Other Operating Expenses | 0.1 | 0.09 | 0.12 | -0 | 0.05 | 0.27 | Upgrade
|
| Operating Expenses | 421.49 | 445.82 | 513.18 | 519.44 | 362.8 | 1,029 | Upgrade
|
| Operating Income | -254.15 | -280.95 | -327.65 | -519.44 | -362.8 | -1,029 | Upgrade
|
| Interest Expense | -0.84 | -0.66 | -0.83 | -1.03 | -1.19 | - | Upgrade
|
| Interest & Investment Income | 28.73 | 30.02 | 40.45 | 17.38 | 12.76 | 0.72 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.56 | 1.56 | 1.18 | 19.99 | -11.33 | -27.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.48 | -0.11 | -0.27 | -0.2 | -0.21 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -225.18 | -250.14 | -287.12 | -483.31 | -362.76 | -1,056 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.83 | 1.3 | - | - | - | 0.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.08 | 0.08 | - | - | 0 | - | Upgrade
|
| Other Unusual Items | 8.75 | 8.57 | 3.15 | -0.18 | 4.85 | 2.31 | Upgrade
|
| Pretax Income | -214.53 | -240.2 | -283.98 | -483.49 | -357.91 | -1,053 | Upgrade
|
| Net Income | -214.53 | -240.2 | -283.98 | -483.49 | -357.91 | -1,053 | Upgrade
|
| Net Income to Common | -214.53 | -240.2 | -283.98 | -483.49 | -357.91 | -1,053 | Upgrade
|
| Shares Outstanding (Basic) | 572 | 576 | 575 | 509 | 459 | 460 | Upgrade
|
| Shares Outstanding (Diluted) | 572 | 576 | 575 | 509 | 459 | 460 | Upgrade
|
| Shares Change (YoY) | -0.78% | 0.26% | 12.97% | 10.91% | -0.25% | - | Upgrade
|
| EPS (Basic) | -0.38 | -0.42 | -0.49 | -0.95 | -0.78 | -2.29 | Upgrade
|
| EPS (Diluted) | -0.38 | -0.42 | -0.49 | -0.95 | -0.78 | -2.29 | Upgrade
|
| Free Cash Flow | -223.66 | -249.53 | -314.04 | -484.59 | -278.59 | -202.83 | Upgrade
|
| Free Cash Flow Per Share | -0.39 | -0.43 | -0.55 | -0.95 | -0.61 | -0.44 | Upgrade
|
| Gross Margin | 99.39% | 97.67% | 100.00% | - | - | - | Upgrade
|
| Operating Margin | -150.94% | -166.45% | -176.61% | - | - | - | Upgrade
|
| Profit Margin | -127.41% | -142.31% | -153.06% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -132.84% | -147.84% | -169.27% | - | - | - | Upgrade
|
| EBITDA | -248.65 | -275.49 | -322.31 | -514.77 | -360.15 | -1,028 | Upgrade
|
| EBITDA Margin | -147.68% | -163.21% | -173.73% | - | - | - | Upgrade
|
| D&A For EBITDA | 5.5 | 5.47 | 5.34 | 4.68 | 2.64 | 0.98 | Upgrade
|
| EBIT | -254.15 | -280.95 | -327.65 | -519.44 | -362.8 | -1,029 | Upgrade
|
| EBIT Margin | -150.94% | -166.45% | -176.61% | - | - | - | Upgrade
|
| Revenue as Reported | 168.37 | 168.79 | 185.53 | - | - | - | Upgrade
|
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.